Purinergic Regulation of the Renal Microcirculation
Purinergic Regulation of the Renal Microcirculation
批准号:
7786252
负责人:
Edward W Inscho
金额:
$30.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-01 至 2013-03-31
关键词:
AddressAdenosineAlbuminsBehaviorBlood PressureChronicEvaluationExcretory functionFibronectinsFibrosisFunctional disorderGelatinase BGlomerular CapillaryHomeostasisHypertensionImpairmentInflammationInflammation MediatorsInflammatoryInfusion proceduresInjuryJuxtamedullary NephronKidneyLeadLinkMeasuresMediatingMicrocirculationMonocyte Chemoattractant Protein-1Plasminogen Activator Inhibitor 1Plasminogen InactivatorsPlatelet ActivationProcessPropertyRattusReceptor ActivationRegulationResearchRisk FactorsRoleSignal TransductionSignaling MoleculeStressTestingTimeTransforming Growth Factorsarterioleclopidogrelin vivokidney vascular structurenormotensivepressureprogramsprotective effectpublic health relevancereceptorresearch studyresponsetransmission processurinaryvascular inflammationvasoconstriction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Autoregulation is an intrinsic property of the preglomerular microvasculature that begins to fail within 6 days of Ang II hypertension resulting in increased transmission of arterial pressure to the glomerulus. Chronic elevation of glomerular capillary pressure is a major risk factor for hypertensive renal injury. The mechanisms responsible for the decline in pressure-mediated autoregulatory vasoconstriction in Ang II hypertension remain unclear. P2X1 receptors are critically important in mediating afferent arteriolar autoregulatory behavior. P2X1 receptor inactivation impairs autoregulatory responses. Ang II hypertension blunts autoregulation by 50% and impairs P2X1 receptor-mediated vasoconstriction and Ca2+ signaling responses. Ang II hypertension, and P2Y12 receptor activation, contribute to inflammation and fibrosis and converge on a loss of autoregulatory efficiency. Clopidogrel selectively blocks ADP sensitive P2Y12 receptors and reduces renal fibrosis without decreasing blood pressure. Clopidogrel also inhibits expression of MCP-1, TGF-?, fibronectin, and PAI-1, all of which are associated with renal injury. Therefore, this competing renewal application will address the central hypothesis that inflammatory processes involving P2Y12 receptor activation contribute to impairment of P2X1 receptor-mediated afferent arteriolar vasoconstriction, impairment of renal autoregulatory control and leads to renal injury in Ang-II-dependent hypertension. Studies will establish the impact of P2Y12 receptor blockade on impaired autoregulation in Ang-II hypertension, afferent arteriolar responsiveness to P2 receptor stimulation and activation of intrarenal inflammatory mediators. Specific aim 1 will test the hypothesis that P2Y12 receptor-dependent inflammatory processes contribute to the decline in autoregulatory control observed in Ang II hypertension. Specific aim 2 will test the hypothesis that P2Y12 receptor-dependent mechanisms contribute to impairment of afferent arteriolar responses to P2 receptor activation resulting in impaired afferent arteriolar autoregulatory behavior. Specific aim 3 will test the hypothesis that P2Y12 receptors stimulate expression of inflammatory mediators that impair renal microvascular reactivity, leading to autoregulatory dysfunction and renal injury. These studies will provide new information on the role of P2Y12 receptors and inflammation on P2 receptor- mediated regulation of renal microvascular function, autoregulatory behavior and the relationship between P2X1 receptor activation and Ang-II hypertensive renal injury.
PUBLIC HEALTH RELEVANCE Hypertensive renal injury is a growing problem in western cultures. Much of the injury relates to pressure- related impairment of renal vascular function. This application will address the mechanisms responsible for hypertension-induced impairment of renal vascular function and its relationship to hypertensive kidney damage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Conference on Control of Renal Function in Health and Disease
-
批准号:9756663
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2019
-
负责人:Edward W Inscho
-
依托单位:
Receptor Specific Mechanisms of Endothelin Control of the Renal Microcirculation
-
批准号:8002583
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
The Inflammatory Cytokines, MCP-1 and TGF-Beta, Mediate Renal Autoregulatory Impa
-
批准号:8011355
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
The cytokines, MCP-1 and TGF-beta, mediate renal autoregulatory impairment
-
批准号:8606758
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
The cytokines, MCP-1 and TGF-beta, mediate renal autoregulatory impairment
-
批准号:8900028
-
项目类别:
-
资助金额:$12.73万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
The cytokines, MCP-1 and TGF-beta, mediate renal autoregulatory impairment
-
批准号:8208158
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
The Inflammatory Cytokines, MCP-1 and TGF-Beta, Mediate Renal Autoregulatory Impa
-
批准号:7753439
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
The cytokines, MCP-1 and TGF-beta, mediate renal autoregulatory impairment
-
批准号:8403967
-
项目类别:
-
资助金额:$34.64万
-
财政年份:2010
-
负责人:Edward W Inscho
-
依托单位:
Autoregulatory Impairment in Salt-Sensitive Hypertension
-
批准号:7433777
-
项目类别:
-
资助金额:$29.38万
-
财政年份:2007
-
负责人:Edward W Inscho
-
依托单位:
Autoregulatory Impairment in Na-Sensitive hypertension
-
批准号:7228245
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2006
-
负责人:Edward W Inscho
-
依托单位:
Autoregulatory Impairment in Na-Sensitive hypertension
-
批准号:7063184
-
项目类别:
-
资助金额:$18.73万
-
财政年份:2005
-
负责人:Edward W Inscho
-
依托单位:
Autoregulatory Impairment in Na-Sensitive hypertension
-
批准号:6853169
-
项目类别:
-
资助金额:$18.18万
-
财政年份:2004
-
负责人:Edward W Inscho
-
依托单位:
RENAL MICROVASCULAR FUNCTION IN AGED RATS
-
批准号:6132483
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2000
-
负责人:Edward W Inscho
-
依托单位:
RENAL MICROVASCULAR FUNCTION IN AGED RATS
-
批准号:6438976
-
项目类别:
-
资助金额:$6.28万
-
财政年份:2000
-
负责人:Edward W Inscho
-
依托单位:
PURINERGIC REGULATION OF THE RENAL MICROVASCULATURE
-
批准号:2143941
-
项目类别:
-
资助金额:$9.32万
-
财政年份:1994
-
负责人:Edward W Inscho
-
依托单位:
PURINERGIC REGULATION OF THE RENAL MICROVASCULATURE
-
批准号:6497884
-
项目类别:
-
资助金额:$22.21万
-
财政年份:1994
-
负责人:Edward W Inscho
-
依托单位:
Purinergic regulation of the renal microvasculature
-
批准号:7021378
-
项目类别:
-
资助金额:$28.87万
-
财政年份:1994
-
负责人:Edward W Inscho
-
依托单位:
Purinergic Regulation of the Renal Microcirculation
-
批准号:8055895
-
项目类别:
-
资助金额:$30.62万
-
财政年份:1994
-
负责人:Edward W Inscho
-
依托单位:
PURINERGIC REGULATION OF THE RENAL MICROVASCULATURE
-
批准号:2458782
-
项目类别:
-
资助金额:$10.24万
-
财政年份:1994
-
负责人:Edward W Inscho
-
依托单位:
PURINERGIC REGULATION OF THE RENAL MICROVASCULATURE
-
批准号:2143940
-
项目类别:
-
资助金额:$11.65万
-
财政年份:1994
-
负责人:Edward W Inscho
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: